Cytomegalovirus Infection Treatment Market, 2012-2023

January 2018 | 216 pages | ID: C6360263004EN
Precision Business Insights (PBI)

Abstracts

Global Cytomegalovirus Infection Treatment Market

Cytomegalovirus (CMV) infection is the common herpes virus infection having different symptoms which occurs in all ages of people around the world. Cytomegalovirus (CMV) infection is a communicable and easily prone through the body fluids like urine, saliva, blood, breast milk and semen. The infection may spread fast from urine or saliva from people who are infected with CMV having virus in their bodily fluids. The disease can transmit from pregnant to baby during delivery. Organ transplant and Blood transfusion are the other way for the transmission of the disease.

Cytomegalovirus infection treatment market is mainly propelling by the rise in the prevalence of CMV infections, growing awareness about herpes disease, pipeline drugs which are promising by key market players for the treatment of CMV infection. Moreover, rise in the support of government, and development of healthcare infrastructure are anticipated to fuel the growth of CMV infection treatment market. However, recent expiries of patented drugs, generic drugs that are available for the treatment like Ganciclovir & Foscarnet are anticipated to hamper the market growth of cytomegalovirus infection treatment.

The global cytomegalovirus infection market is classified on the basis of drug class, infection, distribution channel, and geography.

Based on drug class, the global cytomegalovirus infection market is segmented into the following:

• Antiviral drugs
• Foscarnet
• Cytovene
• Vistide
• Others

Based on infection, the global cytomegalovirus infection market is segmented into the following

• Retinitis
• Pneumonia
• Gastroenteritis
• Others (Mouth Ulcers, Pharyngitis, etc.)

Based on distribution channel, the global cytomegalovirus infection market is segmented into the following:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Global cytomegalovirus infection treatment market is anticipated to show effective growth rate in foresee period. Players in the market are heavily investing in R&D for the development of novel therapies and drugs to treat cytomegalovirus infection. Moreover, regulatory bodies of the healthcare sector are having more attention on novel drugs by giving faster approvals and special status for the drugs. For instance, Merck & Co. Inc., developed Letermovir, antiviral drug for the treatment of CMV infection. The drug has received fast track status by the U.S. FDA and the orphan drug status by European Medicines Agency.

On the basis of Geographical regions, CMV infection treatment market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. North America & Europe were anticipated to contribute major share in the cytomegalovirus infection treatment market due to the high prevalence rate of cytomegalovirus infection. As per Centre for Disease Control and Prevention (CDC), approximately, 80,000 cases of CMV infections were diagnosed in U.S. and Europe. Increased prevalence of cytomegalovirus (CMV) infection in the developing countries and in the areas of lower economic status. Asia-Pacific is anticipated to grow rapidly owing to the large patient pool, and rise in prevalence of many infectious diseases as well as rise in the awareness on cytomegalovirus infections.

Some of the players in cytomegalovirus infection market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.), AiCuris Anti-infective Cures GmbH (Germany) Vical, Inc. (U.S.), Chimerix, Inc. (U.S.) and ViroPharma (U.S.), to name a few

In Feb 2017, Merck & Co., Inc. started pivotal Phase 3 clinical study of letermovir, an antiviral investigational drug for treating clinically significant cytomegalovirus Infectio

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET INTRODUCTION

2.1. Global Cytomegalovirus Infection Treatment Market – Taxonomy
2.2. Global Cytomegalovirus Infection Treatment Market –Definitions
  2.2.1. Drug Type
  2.2.2. Distribution Channel

3. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cytomegalovirus Infection Treatment Market Dynamic Factors - Impact Analysis

4. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis

5. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

5.1. Foscarnet
  5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Cytovene
  5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Vistide
  5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Others
  5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis

6. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET, BY INFECTION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

6.1. Retinitis
  6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Pneumonia
  6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Gastroenteritis
  6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Others (Mouth Ulcers, Pharyngitis, etc.)
  6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis

7. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL CYTOMEGALOVIRUS INFECTION TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

8.1. North America
  8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

9.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Antiviral drugs
    9.1.1.1. Foscarnet
    9.1.1.2. Cytovene
    9.1.1.3. Vistide
    9.1.1.4. Others
9.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.2.1. Retinitis
  9.2.2. Pneumonia
  9.2.3. Gastroenteritis
  9.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)
9.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.3.1. Hospital Pharmacies
  9.3.2. Retail Pharmacies
  9.3.3. Online Pharmacies
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023
9.6. North America Cytomegalovirus Infection Treatment Market Dynamics – Trends

10. EUROPE CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

10.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Antiviral drugs
    10.1.1.1. Foscarnet
    10.1.1.2. Cytovene
    10.1.1.3. Vistide
    10.1.1.4. Others
10.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.2.1. Retinitis
  10.2.2. Pneumonia
  10.2.3. Gastroenteritis
  10.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)
10.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.3.1. Hospital Pharmacies
  10.3.2. Retail Pharmacies
  10.3.3. Online Pharmacies
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Germany
  10.4.2. UK
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Russia
  10.4.7. Poland
  10.4.8. Rest of Europe
10.5. Europe Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023
10.6. Europe Cytomegalovirus Infection Treatment Market Dynamics – Trends

11. ASIA-PACIFIC CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

11.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Antiviral drugs
    11.1.1.1. Foscarnet
    11.1.1.2. Cytovene
    11.1.1.3. Vistide
    11.1.1.4. Others
11.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.2.1. Retinitis
  11.2.2. Pneumonia
  11.2.3. Gastroenteritis
  11.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)
11.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.3.1. Hospital Pharmacies
  11.3.2. Retail Pharmacies
  11.3.3. Online Pharmacies
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Japan
  11.4.2. China
  11.4.3. India
  11.4.4. ASEAN
  11.4.5. Australia & New Zealand
  11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023
11.6. Asia-Pacific Cytomegalovirus Infection Treatment Market Dynamics – Trends

12. LATIN AMERICA CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

12.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Antiviral drugs
    12.1.1.1. Foscarnet
    12.1.1.2. Cytovene
    12.1.1.3. Vistide
    12.1.1.4. Others
12.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.2.1. Retinitis
  12.2.2. Pneumonia
  12.2.3. Gastroenteritis
  12.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)
12.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.3.1. Hospital Pharmacies
  12.3.2. Retail Pharmacies
  12.3.3. Online Pharmacies
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Argentina
  12.4.4. Venezuela
  12.4.5. Rest of Latin America
12.5. Latin America Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Cytomegalovirus Infection Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA CYTOMEGALOVIRUS INFECTION TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

13.1. Drug Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Antiviral drugs
    13.1.1.1. Foscarnet
    13.1.1.2. Cytovene
    13.1.1.3. Vistide
    13.1.1.4. Others
13.2. Infection Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.2.1. Retinitis
  13.2.2. Pneumonia
  13.2.3. Gastroenteritis
  13.2.4. Others (Mouth Ulcers, Pharyngitis, etc.)
13.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.3.1. Hospital Pharmacies
  13.3.2. Retail Pharmacies
  13.3.3. Online Pharmacies
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Gulf Cooperation Council (GCC) Countries
  13.4.2. Israel
  13.4.3. South Africa
  13.4.4. Rest of MEA
13.5. MEA Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2017 – 2023
13.6. MEA Cytomegalovirus Infection Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. F. Hoffmann-La Roche AG (Switzerland)
  14.2.2. GlaxoSmithKline plc (U.K.)
  14.2.3. Merck & Co., Inc. (U.S.)
  14.2.4. AiCuris Anti-infective Cures GmbH (Germany)
  14.2.5. Vical, Inc. (U.S.)
  14.2.6. Chimerix, Inc. (U.S.)
  14.2.7. ViroPharma (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS